Writing Biology’s New Story

Biomolecular Condensates: Our Science

Condensate biology has the potential to fundamentally change the way we target and treat diseases like ALS, FTD and DM1

Latest Updates:

January 25, 2021

Faze Medicines Appoints Biotech Leader Philip Vickers, Ph.D., as Chief Executive Officer

December 10, 2020

Faze Medicines Launches With $81 Million Series A Financing to Leverage New Biology of Biomolecular Condensates to Treat Disease